SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Life Sciences moves up as its arm gets EIR from USFDA for Solid Dosage facility at Salisbury

01 Apr 2020 Evaluate
Jubilant Life Sciences is currently trading at Rs. 260.80, up by 11.95 points or 4.80% from its previous closing of Rs. 248.85 on the BSE.

The scrip opened at Rs. 263.80 and has touched a high and low of Rs. 273.70 and Rs. 251.15 respectively. So far 20826 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 727.05 on 05-Apr-2019 and a 52 week low of Rs. 230.00 on 25-Mar-2020.

Last one week high and low of the scrip stood at Rs. 287.00 and Rs. 233.35 respectively. The current market cap of the company is Rs. 4137.33 crore.

The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 30.09% and 19.24% respectively.

Jubilant Life Sciences’ material wholly owned subsidiary -- Jubilant Pharma, through one of its wholly owned subsidiaries, has received the Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its Solid Dosage Facility at Salisbury, Maryland USA in respect of the inspection conducted by the regulatory agency from February 24, 2020 to February 28, 2020. With the receipt of the EIR, the inspection stands successfully closed. 

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×